Upcoming Issue Highlights
Home Subscribe Advertise Sourcebook Free Product Info Home

Study Shows Promise of Individualized Treatment For Cognitive Decline

EuroMedica
 
Longevity By Nature

A proof-of-concept study led by Heather Sandison, ND, and implemented by researchers at National Cognitive HealthUniversity of Natural Medicine (NUNM) Helfgott Research Institute could have far-reaching, positive impacts on the future of cognitive decline research.

While Alzheimer’s disease (AD) affects approximately 6 million people in the U.S. and 50 million people worldwide, clinical trials have been disproportionately focused on a singular treatment method. Dr. Sandison and team instead tested an individualized, holistic approach to treatment involving changes to patients’ lifestyle, including sleep, diet and stress management.

After initial assessments of unique biomarkers, each trial participant was provided a custom treatment plan, personal health coach and treating clinician. Within six months of intervention, multiple measures of patients’ cognitive function improved, indicating a multimodal, individualized treatment approach may be a more effective strategy than ones involving a single drug.

Dr. Sandison believes these study findings, published in the August issue of the Journal of Alzheimer’s Disease, could be empowering to both patients and providers: “So far, more than 200 AD drugs have failed clinical trials. I hope this research encourages those living with the disease but also motivates researchers to explore previously unaddressed contributors to cognitive decline.”

Study co-author and Director of the NUNM Helfgott Research Institute, Dr. Ryan Bradley, underscored the importance of collaboration in moving AD research forward: “There’s always a knowledge gap and activation energy necessary to move treatments from bench to bedside; these types of partnerships help bridge that gap. Instead of anecdotal evidence of hope or progress, research collaboration offers clinicians quantifiable evidence of patient benefit.”

Drs. Sandison and Bradley hope their initial findings lead to a national multisite control study to further evaluate multimodal, individualized treatment approaches to AD.

“My big push is changing the narrative,” said Dr. Sandison. “As scientists and care providers, we make a lot of assumptions and don’t give patients enough credit. Hopefully these findings chip away at some of those assumptions. The goal is to make Alzheimer’s rare and optional.”

For more information, visit https://nunm.edu.